0001557746 false 0001557746 2025-07-29 2025-07-29

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): July 29, 2025

​

​

Aclaris Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

​

​ | ​ | ​ | ​ | ​
Delaware | ​ | 001-37581 | ​ | 46-0571712
(State or other jurisdiction of incorporation) | ​ | (Commission File Number) | ​ | (IRS Employer Identification No.)

​

701 Lee Road, Suite 103

Wayne, PA 19087

(Address of principal executive offices, including zip code)

​

(484) 324-7933

(Registrant’s telephone number, including area code)

​

N/A

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of Each Class: |  | Trading Symbol(s) |  | Name of Each Exchange on which Registered
Common Stock, $0.00001 par value |  | ACRS |  | The Nasdaq Stock Market, LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 7.01 Regulation FD Disclosure.

​

On July 29, 2025, Aclaris Therapeutics, Inc. (the “Registrant”) will hold a conference call to discuss the top-line results for its Phase 2a clinical trial of ATI-2138, an investigational oral covalent ITK/JAK3 inhibitor, in subjects with moderate to severe atopic dermatitis (the “Top-line Results”). A copy of the presentation that will accompany the conference call is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

​

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

​

Item 8.01 Other Events.

​

On July 29, 2025, the Registrant issued a press release announcing the Top-line Results. A copy of this press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

​

Item 9.01 Financial Statements and Exhibits.

​

(d) Exhibits

Exhibit |  |
Number |  | Exhibit Description
99.1 | ​ | Company Presentation.
99.2 | ​ | Press Release dated July 29, 2025.
104 |  | The cover page from Aclaris Therapeutics, Inc.’s Form 8-K filed on July 29, 2025, formatted in Inline XBRL.

​

​

​

​

​

​

​

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​ | ​ | ACLARIS THERAPEUTICS, INC.
​ | ​ | ​
​ | By: | /s/ Kevin Balthaser
Date: July 29, 2025 | ​ | Kevin Balthaser
​ | ​ | Chief Financial Officer

​

​

3